Citi Reinstates Buy on Becton Dickinson After Life Sciences Divestiture
Citi resumed coverage of Becton Dickinson (BD) with a Buy rating and a $233 price target, saying the pending sale of BD's Life Sciences Bioprocessing unit reconfigures the company into a focused medical technology operator across four businesses. Citi highlighted the addressable market, expected use of sale proceeds, near-term reporting dynamics an…